IHS Chemical Week

People & Business :: M&A

Sun Pharma to acquire Ranbaxy for $3.2 billion

11:45 AM MDT | April 7, 2014 | Deepti Ramesh

Sun Pharmaceutical Industries (Mumbai) says it has agreed to acquire 100% of Ranbaxy Laboratories (Gurgaon, India) in an all-stock transaction, which has a total equity value of about $3.2 billion. The combination of Sun Pharma and Ranbaxy will create the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India. Ranbaxy shareholders, under the agreement, will receive 0.8 share of Sun Pharma for each share of Ranbaxy. The proposed acquisition has been approved by the boards of directors of Sun Pharma and Ranbaxy as well...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa